Combinations of Biomarkers and Milan Criteria for Predicting Hepatocellular Carcinoma Recurrence After Liver Transplantation

Growing evidence suggests that pretransplant alpha-fetoprotein (AFP) predicts outcomes of hepatocellular carcinoma (HCC) patients treated with liver transplantation. We aimed to determine whether pretransplant AFP, Lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3), and des-gamma-carboxyprothrombin (DCP) predicted HCC recurrence after transplantation. A retrospective cohort study of 313 HCC patients undergoing transplantation between 2000 and 2008 was conducted, and 48 (15.3%) developed recurrence during a median follow-up of 90.8 months. The 127 patients with available serum drawn before transplantation were included; they included 86 without recurrence and 41 with recurrence. Serum was tested for AFP, AFP-L3%, and DCP in a blinded fashion with the TASWako i30 immunoanalyzer. All biomarkers were significantly associated with HCC recurrence. The hazard ratios (HRs) were 3.5 [95% confidence interval (CI), 1.9-6.7; P<0.0001] for DCP7.5 ng/mL and 2.8 (95% CI, 1.4-5.4; P=0.002) for AFP250 ng/mL. The HR increased to 5.2 (95% CI, 2.3-12.0; P<0.0001) when AFP250 ng/mL and DCP 7.5 ng/mL were considered together. When they were combined with the Milan criteria, the HR increased from 2.6 (95% CI, 1.4-4.7; P=0.003) for outside the Milan criteria to 8.6 (95% CI, 3.0-24.6; P<0.0001) for outside the Milan criteria and AFP250 ng/mL and to 7.2 (95% CI, 2.8-18.1; P<0.0001) for outside the Milan criteria and DCP 7.5 ng/mL. Our findings suggest that biomarkers are useful for predicting the risk of HCC recurrence after transplantation. Using both biomarkers and the Milan criteria may be better than using the Milan criteria alone in optimizing the decision of liver transplantation eligibility. Liver Transpl 21:599-606, 2015. (c) 2015 AASLD.